STRATA®
Report
- Report Number
- 9612501-2022-00599
- Event Type
- Death
- Date Received
- April 19, 2022
- Date of Event
- November 2, 2020
- Report Date
- April 19, 2022
- Manufacturer
- COVIDIEN LLC
- Product Code
- JXG
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- BR
- Reporter Occupation
- OTHER HEALTH CARE PROFESSIONAL
- Health Professional
- Yes
Narratives
PATIENT AGE IS THE MEAN VALUE OF PATIENTS IN THE STUDY. PATIENT GENDER IS THE MAJORITY VALUE OF PATIENT IN THE STUDY. PATIENT WEIGHT NOT AVAILABLE FROM THE SITE. EVENT DATE IS THE ONLINE PUBLISHING DATE OF THE LITERATURE ARTICLE. DEVICE LOT NUMBER, OR SERIAL NUMBER, UNAVAILABLE. 510(K) IS DEPENDENT UPON THE DEVICE MODEL NUMBER AND THEREFORE, UNAVAILABLE. NO PARTS HAVE BEEN RECEIVED BY THE MANUFACTURER FOR EVALUATION. DEVICE MANUFACTURING DATE IS DEPENDENT ON LOT NUMBER/SERIAL NUMBER, THEREFORE, UNAVAILABLE. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.
OLIVEIRA, M.F., BOA SORTE JR., A.A., EMERENCIANO, D.L., ROTTA, J.M., MENDES, G.A.S., PINTO, F.C.G. LONG TERM FOLLOW-UP OF SHUNTED IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS PATIENTS: A SINGLE CENTER EXPERIENCE. ACTA NEUROLOGICA BELGICA (2021) 121:1799¿1806. HTTPS:// DOI.ORG/10.1007/S13760-020-01538-5 ABSTRACT IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS (INPH) IS A CONDITION CHARACTERIZED BY GAIT DISTURBANCE, DEMENTIA AND/OR URINARY INCONTINENCE AND ENLARGED VENTRICULAR SYSTEM DUE TO DISTURBANCE OF CEREBROSPINAL FUID (CSF). THIS STUDY AIMS TO DESCRIBE THE LONG-TERM EXPERIENCE WITH PATIENTS WITH INPH SUBMITTED TO VENTRICULOPERITONEAL SHUNT (VPS) WITH THE PROGRAMMABLE VALVE STRATA® (MEDTRONIC). WE PROSPECTIVELY SELECTED A COHORT OF PATIENTS WITH A DIAGNOSIS OF INPH FROM JANUARY 2010 TO APRIL 2013 IN A BRAZILIAN TERTIARY HOSPITAL. ALL PATIENTS UNDERWENT CLINICAL EVALUATION, WHICH CONSISTS OF THE MINI-MENTAL STATE EXAMINATION AND TIME UP AND GO TESTS AND THE APPLICATION OF JAPANESE SCALE FOR IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS IN THREE STAGES: PRIOR TO THE TT, 3 H AFTER THE TT AND 72 H AFTER THE TT. FIFTY PATIENTS WERE SUBMITTED TO VPS AND FOLLOWED. THERE WERE 32 MEN AND 18 WOMEN. MEAN AGE WAS 77.1 WITH STANDARD DEVIATION OF 10.9. FOLLOW-UP TIME RANGED FROM 96 TO 120 MONTHS, WITH MEAN OF 106 MONTHS. AFTER 1 YEAR OF FOLLOW-UP, 42 (83%) PATIENTS PRESENTED WITH CLINICAL IMPROVEMENT, DECREASING TO 62% OF PATIENTS AT MID-TERM FOLLOW-UP AND 38% OF PATIENTS AT LATE FOLLOW-UP. COMPLICATIONS OCCURRED IN 18% OF SUBJECTS, NEEDING REOPERATION IN 16%. OUR RESULTS SHOW RELEVANT CLINICAL IMPACT OF SHUNTING IN INPH PATIENTS, DECREASING OVER TIME. COMPLICATIONS SHOULD NOT BE UNDERESTIMATED, REACHING UP TO 18% AND DEMANDING REOPERATION IN 16% OF CASES. THUS, ALTHOUGH MUCH HAS BEEN IMPROVED WITH CURRENT SHUNT TECHNOLOGY, IT IS STILL IMPORTANT TO CONSIDER THE DRAWBACKS OF TREATMENT. REPORTED EVENTS: ONE PATIENT WITH OVER DRAINAGE, SUBDURAL HEMATOMA AND INFECTION PRESENTED WITH SUBDURAL EMPYEMA AND DIED INSTEAD OF SURGERY AND ANTI BIOTICS TREATMENT.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 2619950 | STRATA® | SHUNT, CENTRAL NERVOUS SYSTEM AND COMPONENTS | JXG | COVIDIEN LLC | UNKNOWN-S |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 77 YR | Male | Death |